Abstract Lactoperoxidase (LPO) is a 78 kDa hemecontaining oxidation-reduction enzyme present in milk, found in physiological fluids of mammals. LPO has an antimicrobial activity, and presumably contribute to the protective functions of milk against infectious diseases. In this study, recombinant vaccinia virus expressing bovine LPO (vv/bLPO) was constructed. In rabbit kidney (RK13) cells infected with vv/bLPO, recombinant bLPO was detected in both cell extracts and culture supernatants. Tunicamycin treatment decreased the molecular weight of recombinant bLPO, indicating that recombinant bLPO contains a N-linked glycosylation site. The replication of recombinant vaccinia viruses expressing bovine lactoferrin (vv/bLF) at a multiplicity of infection (moi) of 5 plaque-forming units (PFU)/cell was inhibited by antiviral activity of recombinant bLF, suggesting that vv/bLF has an antiviral effect against vaccinia virus. On the other hand, the replication of vv/bLPO at a moi of 5 PFU/cell was not inhibited by antiviral activity of recombinant bLPO, indicating that this recombinant virus could be used as a suitable viral vector. These results indicate that a combination of bLPO and vaccinia virus vector may be useful for medical and veterinary applications in vivo.
Introduction
Lactoperoxidase (LPO), a heme-containing oxidation-reduction enzyme present in milk and saliva, is part of an antimicrobial system, and converts thiocyanate (SCN -) to hypothiocyanate (OSCN -) in a hydrogen peroxide (H 2 O 2 )-dependent reaction. The molecular weight of LPO is approximately 78 kDa, and the carbohydrate moiety comprises about 10% of the total weight (Mansson-Rahemtulla et al. 1988) . Lactoperoxidase, myeloperoxidase (MPO), eosinophil peroxidase (EPO) and thyroid peroxidase (TPO) belong to the homologous mammalian peroxidase family and share 50-70% identity. Even higher homology can be found among their active siterelated residues. These peroxidases can catalyze oxidation of halides and pseudohalides such as thiocyanate by hydrogen peroxide to form potent oxidant and bactericidal agents. Myeloperoxidase has been shown to inactivate influenza virus (Yamamoto et al. 1991) and HIV-1 virus (Klebanoff and Kazazi 1995) . Human recombinant MPO has been shown to have a virucidal effect on HIV-1 virus (Moguilevsky et al. 1992; Chochola et al. 1994 ) and cytomegalovirus (El Messaoudi et al. 2002) . However, few studies have examined whether LPO inhibits virus infection in vitro and in vivo.
Vaccinia virus belongs to the family of Poxviridae, and is the most intensively studied member of the poxvirus family (Moss 1990) . Poxviruses replicate in the cytoplasm of infected cells without using nuclear enzymes of the host cells for transcription or DNA synthesis. Vaccinia virus has circumvented the need for nuclear enzymes by encoding or packaging a complete enzyme system for transcription (Moss 1990 ) and DNA synthesis, including a DNA-dependent DNA polymerase (Moss and Cooper 1982) , DNA topoisomerase (Shuman and Moss 1987) and DNA ligase (Kerr and Smith 1989) . Consequently, the vaccinia virus is widely used as an expression system in molecular biotechnology. Recombinant vaccinia virus has been demonstrated to be an effective antigen delivery system for infectious diseases in many species, with rabies and rinderpest being notable examples (Ertl and Xiang 1996; Tsukiyama et al. 1989 ). In addition recombinant vaccinia virus can give rise to long-term immunity (Inui et al. 1995) . In previous studies, recombinant vaccinia virus has been also used to produce cytokines (e.g., interferon-b, interferon-c; Kohonen-Corish et al. 1989; Nishikawa et al. 2000 Nishikawa et al. , 2001 , but it has not yet been used for expression of antimicrobial milk proteins such as bovine LPO (bLPO). In the present study, we constructed recombinant vaccinia virus that expresses bLPO, and characterized production of bLPO, and replication of the recombinant virus. The expression and characterization of bLPO produced by recombinant vaccinia virus may be useful for the treatment of infectious diseases in humans or animals (Tanaka et al. 2006 ).
Materials and methods

Cells and viruses
Rabbit kidney (RK13) cells were cultured in Eagle's minimum essential medium (EMEM, Sigma Chemicals Co., St Louis, MO, USA) supplemented with 8% heat-inactivated fetal bovine serum (FBS). Vaccinia virus LC16mO (mO) strain and its recombinant were propagated in RK13 cells in EMEM supplemented with 8% FBS.
Construction of recombinant vaccinia virus that expresses bLPO and bovine lactoferrin
The open reading frame of bLPO was amplified by reverse transcriptase polymerase chain reaction (RT-PCR) from bovine mammary gland cDNA using a pair of primers, 5 0 -ATAGACGGTATAAAAGGC CGG-3 0 and 5 0 -CTGAGTCTACTTGAAATGG CATCG-3 0 . The length of the PCR products covered the full length of bLPO (2,295 bp). The sequence analysis was done using an Applied Biosystems sequencer (Foster City, CA, USA). bLF cDNA was amplified from mamary glands cells, using RT-PCR with primers designed from bLF cDNA (Tanaka et al. 2003a ). The PCR products were blunted by T4 DNA polymerase and ligated with the vaccinia virus transfer vector pAK8 (Yasuda et al. 1990) , which was cut with Sal I and then blunted. The plasmid (pAK/bLPO or pAK/bLF) was transfected into RK13 cells using a lipofectin reagent (Life Technologies, Tokyo, Japan) for 1 h after infection with the mO strain. After 2 days of incubation, culture medium was collected. We isolated recombinant virus (vv/bLPO or vv/bLF) produced by homologous recombination between pAK8 and mO strain in the viral thymidine kinase negative (TK -) cells in the presence of 100 lg/ml 5-bromo-2 0 -deoxyuridine, selecting TK -viruses by plaque isolation.
Immunofluorescence test RK13 cells were infected with mO, vv/bLPO (5 plaque-forming units [PFU]/cell, 48 h), and subjected to IFAT. The infected RK13 cells were fixed with acetone, and incubated with mouse anti-bLPO monoclonal antibody (anti-bLPO mAb) or rabbit anti-bLPO polyclonal antibody (anti-bLPO Ab); these antibodies were produced by the present authors (Tanaka et al. 2003b; Watanabe et al. 1998) . The cells were then stained with fluorescein-conjugated goat anti-mouse antibody (Southern Biotechnology Associates Inc., Birmingham, AL, USA) or fluorescein-conjugated sheep anti-rabbit antibody (Waco Pure Chemical, Osaka, Japan). The cells were observed using fluorescence microscopy.
Sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot analysis RK13 cells in tissue culture (colony diameter, 15 mm) were infected with the mO strain or the recombinant vaccinia virus at a multiplicity of infection (moi) of 5 PFU/cell for 1 h at 37°C. Then, the cells were washed with EMEM and cultured in 500 ll of EMEM at 37°C for 12-72 h. The cell extracts were prepared by sonication. The cell extracts and culture supernatants were subjected to SDS-PAGE under reducing conditions, followed by electro transfer of proteins to a PVDF membrane (Osmonics Inc., Westborough, MA, USA). The membrane was immersed in blocking buffer (phosphate-buffered saline [PBS] containing 3% bovine serum albumin) at 4°C overnight, incubated with anti-bLPO Ab (diluted in the blocking buffer) at 37°C for 1 h. The membrane was washed 3 times with PBS, and then incubated with alkaline phosphatase-conjugated goat anti-rabbit IgG antibodies (Promega Co., Madison, WI, USA; diluted in the blocking buffer) at 37°C for 1 h. The membrane was visualized by incubation with BCIP/NBT colour substrate (Promega Co.).
Tunicamycin treatment
Recombinant vaccinia virus-infected RK13 cells at a moi of 5 PFU/cell were incubated in EMEM containing 1 lg/ml tunicamycin (Sigma Chemicals Co.), which is a reagent that prevents synthesis of N-linked sugars, for 48 h post-infection (pi). The cells were then harvested, and the cell lysate was subjected to Western blot analysis to assay for expression of recombinant proteins.
Virus growth analysis RK13 cells were infected with mO or recombinant viruses at a moi of 5 PFU/cell. After 1 h, the infected cells were washed with EMEM and cultured for 12-72 h after viral infection. Virus titers were determined by plaque titration according to Nishikawa et al. (2000) . Data from this experiment were evaluated using Student's t test. The 95% level of significance was used in the analysis.
Results
Expression of bLPO by recombinant vaccinia virus in RK13 cells
Vaccinia virus mO strain and pAK/bLPO were allowed to infect RK13 cells, and virus-containing medium of the infected RK13 cells was collected and analyzed by IFAT or Western blotting for the presence of recombinant bLPO. A recombinant bLPO-expressing clone was selected by the plaqueassay technique. vv/bLPO-infected cells were examined by IFAT and reacted with both anti-bLPO mAb (Fig. 1b) and anti-bLPO Ab (Fig. 1c) . mO-infected cells served as negative reference and were labeled with both antibody reagents (Fig. 1a) . The recombinant vaccinia virus, vv/bLPO coding for bLPO under the control of P 7.5 promoter, was constructed by the homologous recombination method. To examine the expression of recombinant bLPO, RK13 cells were infected with mO or vv/bLPO at a moi of 5 PFU/cell. A recombinant bLPO band at 90 kDa was detected in cell extracts by Western blot analysis using antibLPO Ab after 48 h (Fig. 2a lane 4) . Recombinant bLPO was also secreted into the supernatant, as indicated by recombinant bLPO bands at 88 and 90 kDa (Fig. 2b lane 4) . The apparent molecular weight of these recombinant bLPO molecules (88 and 90 kDa) was greater than that of native bLPO (78 kDa). This result indicated that carbohydrate structure and amino acid sequence between recombinant bLPO and native bLPO were different. To test whether the increase of molecular weights in recombinant bLPO was due to glycosylation, the infected cells were treated with tunicamycin. As a result, no protein was secreted into the supernatant by infected cells treated with tunicamycin (Data not shown). In the cell extracts, the apparent molecular weight of bLPO was reduced to 80 kDa, indicating that recombinant bLPO were modified by N-linked sugars (Fig. 3 lane 4) . The 90 kDa molecule would be a proprotein.
Time course of bLPO production in the recombinant vaccinia virus system
To analyze the kinetics of expression of bLPO gene products, culture supernatants from RK13 cells infected with vv/bLPO were collected for 12-72 h pi. Recombinant bLPO were first detectable in culture supernatant at 24 h pi (Fig. 4 lane 2) . The amount of recombinant bLPO increased 36-48 h pi, and reached plateau levels by 72 h pi (Fig. 4 lane 3-6 ).
Growth analysis of vv/bLPO in RK13 cells
The growth curves of mO, vv/bLPO and recombinant vaccinia viruses expressing bovine lactoferrin (vv/ bLF) are compared in Fig. 5 . Peak titers (reached at 48 h pi) of mO, vv/bLPO and vv/bLF were 1.6 9 10 5 , 1.6 9 10 5 , and 0.2 9 10 5 plaque-forming units (PFU)/ml, respectively. These results indicate that bLF, but not bLPO, inhibits growth of recombinant virus in infected RK13 cells. There were no significant differences in growth between mO and vv/ bLPO until 72 h pi (p [ 0.05, Student's t test mO vs. 
Discussion
The expression systems using recombinant baculovirus or Chinese hamster ovary cells have been used to express bLPO (Tanaka et al. 2003b; Watanabe et al. 1998) . However, there have been no previous reports of the use of vaccinia virus to express bLPO. The available evidence suggests that growth of vaccinia virus is inhibited by expression of bLPO. In the present study, recombinant vaccinia virus expressing bLPO (vv/bLPO) was constructed. RK13 cells were infected with vv/bLPO, and we characterized virus growth and post-translation modifications of the resultant product. Recombinant bLPO extracted from cell extracts and culture supernatants had an apparent molecular weight of 88 and 90 kDa, which is greater than that of native bLPO (78 kDa) in Western blot analysis. These size differences may be due to a difference in glycosylation level and differences in processing between RK13 cells and the mammary gland. When the infected RK13 cells were treated with tunicamycin, the apparent molecular weight of recombinant bLPO in the cells was 80 kDa, suggesting that recombinant bLPO is modified by N-linked glycosylation. Tunicamycin treatment completely abolished secretion of bLPO, indicating that N-linked glycosylation is essential for bLPO secretion. Therefore, recombinant bLPO was differentially processed during synthesis and secretion from RK13 cells compared with the mammary gland. A similar situation was previously reported for recombinant bLPO expressed in insect cells (Tanaka et al. 2003b) . Interestingly, the molecular weight of recombinant bLPO produced in RK13 cells was higher than that expressed in insect cells. The carbohydrate structure analysis of purified recombinant bLPO expressed in insect cells and native bLPO found different reactivity with PHA-E4, PNA, and RCA120 by using lectin assay (Tanaka et al. 2003b) . Therefore, the glycosylation level of recombinant protein might also be different between RK13 cells and insect cells. Most of the bLPO extracted from milk showed Asp-101 as the N-terminal amino acid residue (Dull et al. 1990; Watanabe et al. 2000) . However, Watanabe et al. (2000) found also that different preparations of bLPO showed a different N-terminal amino acid residue. These variations may result from differences in the disk-electrophoresis and ion-exchange chromatography methods used for analysis (Carlström 1969) . Thus, it might be possible that the 90 kDa form of recombinant bLPO did not undergo proteolysis, whereas the 88 kDa form of recombinant bLPO be the result of proteolysis of some N-terminal amino acid residues during synthesis and secretion by Rk 13 cells as observed for bLPO synthesized by the mammary gland. Bovine Lactoferrin is a 80 kDa iron-binding glycoprotein found in physiological fluids of mammals. bLF has also an antimicrobial activity as bLPO, and presumably contributes to the protective functions of milk against infectious diseases. In RK13 cells infected with vv/bLF, recombinant bLF was detected in both cell extracts and culture supernatants (Data not shown). However, the replication of vv/bLF at a moi of 5 PFU/cell was inhibited by the antiviral activity of recombinant bLF, suggesting that vv/bLF has an antiviral effect against vaccinia virus. On the other hand, the expression of bLPO was also detected in cell extracts and culture supernatants of the vv/ bLPO-infected cells as well as vv/bLF-infected cells. However, the replication of vv/bLPO at a moi of 5 PFU/cell was not inhibited by antiviral activity of recombinant bLPO, because LPO catalyzes oxidation of endogenous thiocyanate (SCN -) to produce hypothiocyanate (OSCN -) only in the presence of hydrogen peroxide (H 2 O 2 ). These products have a broad-spectrum antimicrobial and antiviral activity (Shin et al. 2001 (Shin et al. , 2005 . Therefore due to the absence of thiocyanate (SCN -) and/or hydrogen peroxide (H 2 O 2 ) the replication of recombinant virus is not inhibited by recombinant bLPO.
Studies indicate that gene therapy using viral vectors containing the bLPO gene can produce anti microbial and anti-tumor activity (Odajima et al. 1996; Stanislawski et al. 1989) . The major problem with such viral vectors is their attenuation. The recombinant vaccinia viruses in this report are TK -in phenotype that may reduce pathogenicity in vivo (Buller et al. 1985) because of insertion of the bLPO gene into the TK gene. Our results demonstrate the attenuation of the viral pathogenicity by introduction of the bLPO gene into vaccinia virus. Thus fine tuning of bLPO activity, may allow the control of virulence of vaccinia virus vector necessary for medical and veterinary applications in vivo.
